Log In

 

Company Name : Ferring Pharmaceuticals

Tuesday, February 14, 2017 2:29AM IST (8:59PM GMT)

(BW)(FERRING-PHARMACEUTICALS)

Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement


Saint-Prex, Switzerland

Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary and unique Stabilized Injectable Formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic.

 

Under the terms of the agreement, Ferring will fund the development work and, upon completion, Ferring will have the right to exercise its option and enter into a definitive agreement with Foresee. Execution of a definitive agreement would entitle Foresee to additional payments including upfront, milestones and royalties based on net sales of the product(s) commercialized by Ferring.

 

“We have been impressed with Foresee’s achievements to date and we see value in its SIF platform technology,” said Alan S. Harris, Senior Vice President, R&D Executive Office at Ferring. “The technical barriers Foresee has overcome in developing stable, formulated peptides in solution for controlled release therapy for three and six-month durations of action after a single injection are quite significant, and this gives us much confidence in the potential of the SIF platform applied to complex peptide drug substances. We are enthusiastic about this new collaboration.”

 

“We are excited about entering into this collaboration with Ferring, a global specialty pharmaceutical company with a long-standing history of innovation in the area of injectable therapeutic peptides and the application of novel formulations and delivery technologies to generate differentiated product profiles,” said Dr. Ben Chien, Chairman and CEO of Foresee. “We are confident that our SIF platform will provide significant value to Ferring’s R&D product portfolio and very much look forward to working with them on this project.”

 

ENDS

 

About Ferring Pharmaceuticals

 

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

 

About Foresee Pharmaceuticals

 

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery platform and derived drug products targeting large specialty markets, and its transformative early stage preclinical and clinical NCE programs targeting inflammatory & fibrotic diseases and other disease areas with high unmet needs. Foresee has a product portfolio including late stage and early stage programs such as FP-001, a stable, premixed, prefilled version of leuprolide depot for injection, which has recently successfully completed a global Phase III Registration Study and FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, which is currently completing a Phase 1 study.

 

 

 

 


Click here for Media Contact Details
CONTACTS : Ferring Pharmaceuticals Lindsey Rodger Tel. +41 58 451 40 23 lindsey.rodger@ferring.com or Foresee Pharmaceuticals Mathieu Boudreau, Ph.D. Tel. +1 514 806 9036 mathieu.boudreau@foreseepharma.com

More News from Ferring Pharmaceuticals

02/06/2017 10:52PM

Ferring Appoints Aaron Graff to Executive Board

Ferring Pharmaceuticals announced that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective ...

30/05/2017 10:12AM

World Bedwetting Day Steering Committee: New global guidelines call for more effective treatment for bedwetting, a common condition which affects 1 in 15 children1

Bedwetting affects 1 in 15 seven year olds1 Boys are twice as likely to suffer as girls and the risk is 44% if one parent wet the bed and 77% if both did, suggesting a genetic link2 Bedwetting has a serious ...

10/04/2017 6:15PM

Ferring Announces Exclusive Agreement with Alrise Biosystems for the Development of an Injectable, Controlled-Release Peptide

Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology ...

Similar News

27/06/2017 7:14PM

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in ...

No Image

27/06/2017 7:02PM

Takeda and Biological E. Limited Announce Partnership to Develop Low-Cost Combination Vaccines for Low- and Middle-Income Countries around the Globe

Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Biological E. Limited (“BE”) announced that they have entered into a collaboration whereby two licensing agreements to ...